AstraZeneca Says AIRSUPRA Now Commercially Available In US As FDA-approved Option For Asthma
(RTTNews) - AstraZeneca (AZN, AZN.L) announces Monday that AIRSUPRA (albuterol/budesonide) is now commercially available in the US by prescription. AIRSUPRA was approved based on the results from two Phase III trials, MANDALA and DENALI.
AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older.
AIRSUPRA contains a short-acting beta2-agonist (SABA) to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to help decrease inflammation in the lungs.
read more
Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial
Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
RTTNews
|
113 days ago
Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program
Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
RTTNews
|
119 days ago
AstraZeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases
AstraZeneca plc (AZN) said Friday it has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA) to help protect access to medicines for cancer and rare disease patients.
RTTNews
|
249 days ago
AstraZeneca Q2 Profit Surges, Signs Gene Therapy Deal With Pfizer; Stock Up
Shares of AstraZeneca Plc were gaining around 4 percent in London trading as well as around 5 percent in pre-market activity on Nasdaq after the British drug major reported Friday significantly higher profit for its second quarter. Top line beat market estimates. Further, the company maintained its outlook for fiscal 2023, expecting growth. In addition, AstraZeneca noted that its Rare Disease ...
RTTNews
|
277 days ago
AstraZeneca Partners Vanguard Renewables To Use Renewable Natural Gas In The U.S. By End Of 2026
In a first-of-its-kind collaboration, British drug major AstraZeneca plc (AZN, AZN.L) is partnering with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of its sites in the United States by the end of 2026.
RTTNews
|
322 days ago
BioLight Inks Agreement With Alexion To Explore Technology For Diagnosis Of Retinal Diseases
BioLight Life Sciences Ltd. announced Tuesday it has signed a research collaboration agreement with Alexion Pharmaceuticals, Inc. (ALXN), a subsidiary of AstraZeneca plc (AZN, AZN.L), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases.
RTTNews
|
336 days ago
AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus
Immuno-pharma company AIM ImmunoTech Inc. (AIM) announced Tuesday it has entered into an external sponsored collaborative clinical research agreement with Netherland-based Erasmus University Medical Center and AstraZeneca plc. (AZN, AZN.L).
RTTNews
|
469 days ago
Illumina In Research Collaboration With AstraZeneca To Accelerate AI-based Drug Target Discovery
Illumina, Inc. (ILMN) announced Tuesday a strategic research collaboration with British drug major AstraZeneca plc (AZN.L, AZN) to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise.
RTTNews
|
567 days ago
